Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Decline in Short Interest

Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) was the recipient of a large drop in short interest in October. As of October 30th, there was short interest totaling 3,236,659 shares, a drop of 46.9% from the October 15th total of 6,094,189 shares. Approximately 5.9% of the shares of the stock are short sold. Based on an average daily volume of 1,127,185 shares, the days-to-cover ratio is currently 2.9 days.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP lifted its stake in Protara Therapeutics by 120.1% during the third quarter. Marshall Wace LLP now owns 1,543,284 shares of the company’s stock valued at $4,707,000 after buying an additional 842,263 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Protara Therapeutics by 86.7% in the first quarter. Bank of America Corp DE now owns 925,918 shares of the company’s stock worth $4,824,000 after buying an additional 430,014 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Protara Therapeutics by 133.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,267 shares of the company’s stock worth $2,767,000 after buying an additional 304,110 shares during the period. Walleye Capital LLC boosted its holdings in shares of Protara Therapeutics by 204.0% in the first quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock worth $2,310,000 after buying an additional 297,525 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of Protara Therapeutics in the second quarter worth approximately $526,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Price Performance

NASDAQ TARA opened at $2.53 on Monday. The company’s 50 day simple moving average is $2.89 and its 200 day simple moving average is $4.39. Protara Therapeutics has a 12 month low of $2.09 and a 12 month high of $7.82. The company has a market capitalization of $155.77 million, a P/E ratio of -1.82 and a beta of 1.54.

Protara Therapeutics (NASDAQ:TARA – Get Free Report) last released its earnings results on Friday, November 6th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.02. On average, analysts anticipate that Protara Therapeutics will post -1.37 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on TARA. Cantor Fitzgerald reiterated an “overweight” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Wall Street Zen upgraded Protara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $26.25.

Read Our Latest Research Report on TARA

About Protara Therapeutics

(Get Free Report)

Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use. The company’s lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease. Protara was formed in 2019 through a merger involving ArTara Therapeutics.

See Also

Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.